+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
siRNA Therapeutics Market - Global Forecast 2026-2032- Product Image
siRNA Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

siRNA Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6090381
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The siRNA Therapeutics Market is projected to reach USD 3.58 Billion in 2026. It is expected to continue growing at a CAGR of 10.68%, reaching USD 6.61 Billion by 2032.

siRNA Therapeutics: Executive Overview

Small interfering RNA (siRNA) therapeutics are medicines designed to selectively silence specific genes by directing cellular machinery to degrade complementary messenger RNA. Their clinical value rests on high target specificity, the ability to address previously difficult protein targets, and the potential for infrequent dosing when delivery systems support durable activity. The field is advancing through improvements in sequence design, chemical stabilization, conjugation, and tissue-directed delivery.

Delivery, Durability, and Translational Progress Are Reshaping the Field

The landscape is shifting from proof of gene silencing toward reliable delivery to clinically relevant tissues. Ligand conjugates, lipid-based systems, and other delivery approaches are being refined to improve uptake, reduce off-target effects, and extend pharmacologic activity. Progress is also being shaped by biomarker-guided development, clearer dose-response characterization, and increasing attention to manufacturing consistency, long-term safety, immune effects, and treatment access.

Artificial Intelligence Accelerates Design, Prioritization, and Development

Artificial intelligence is contributing to siRNA discovery by supporting target identification, sequence optimization, off-target prediction, delivery-material selection, and analysis of transcriptomic and clinical datasets. Its cumulative impact depends on the quality and diversity of training data, experimental validation, and transparent model governance. AI can shorten iteration cycles and improve candidate prioritization, but it does not replace laboratory confirmation, toxicology, regulatory review, or post-treatment monitoring.

Regional Insights: Delivery Capability and Regulatory Readiness Shape Adoption

North America benefits from established biotechnology infrastructure, clinical research capacity, and substantial experience with advanced therapeutics. Europe combines strong academic translational networks with coordinated regulatory and health-technology assessment considerations. Asia-Pacific is supported by expanding biopharmaceutical capabilities and significant research activity, while regional differences in reimbursement and clinical infrastructure remain important. Latin America is developing specialized research and treatment capacity, with access and supply-chain reliability continuing to influence implementation. The Middle East is strengthening precision-medicine and innovation ecosystems, whereas Africa requires sustained investment in clinical networks, diagnostics, cold-chain logistics, and equitable access.

Group Insights: Cooperation and Policy Alignment Influence Scale

ASEAN markets present varied regulatory systems, healthcare capacity, and access conditions, making regional cooperation especially relevant. BRICS members combine large scientific and patient populations with diverse development and reimbursement environments. The European Union offers regulatory coordination alongside country-level differences in health technology assessment and procurement. G7 countries contribute advanced research, manufacturing, and financing capabilities. GCC states are investing in healthcare modernization and precision medicine, while NATO members provide broad research and industrial networks; these groupings are not uniform markets, so implementation strategies must account for national policy and infrastructure differences.

Country Insights: National Strengths Create Different Development Pathways

The United States and Canada combine strong research systems with experienced clinical-development environments. The United Kingdom, Germany, France, Italy, and Spain offer established academic and healthcare networks, while differences in assessment, procurement, and reimbursement affect uptake. China, Japan, South Korea, India, and Australia are strengthening research, manufacturing, and translational capabilities through distinct regulatory and healthcare frameworks. Brazil and Mexico are important Latin American centers for clinical activity and healthcare delivery, with access shaped by institutional capacity and supply chains. Russia maintains scientific and clinical capabilities, although collaboration, procurement, and regulatory conditions require careful assessment.

Strategic Priorities for Leaders in siRNA Therapeutics

Industry leaders should prioritize delivery platforms matched to tissue biology, incorporate off-target and immune-risk testing early, and use clinically meaningful biomarkers to demonstrate durable response. Development plans should integrate manufacturing controls, scalable analytical methods, and clear long-term follow-up. Partnerships with hospitals, diagnostic providers, regulators, and patient organizations can improve trial execution and access planning. AI should be deployed with validated datasets, human oversight, reproducible workflows, and explicit controls for bias, privacy, and model drift. Regional launch strategies should reflect local reimbursement, infrastructure, and treatment-monitoring requirements rather than assuming a uniform global pathway.

Research Methodology: Evidence-Based Assessment of the siRNA Therapeutics Landscape

This executive summary uses a structured synthesis of publicly available scientific literature, clinical-trial records, regulatory documents, health-system information, and authoritative policy and technology sources. Evidence was assessed qualitatively for relevance, recency, methodological strength, and geographic applicability. Findings were organized around therapeutic mechanisms, delivery technologies, development practices, artificial-intelligence applications, and regional, group, and country conditions. No market estimates, market sizing, market shares, or forecasts are presented.

Conclusion: Precision Delivery and Evidence Discipline Will Define Progress

siRNA therapeutics are moving toward a more mature model in which selective gene silencing must be paired with dependable tissue delivery, durable benefit, manageable safety, and practical treatment access. Scientific progress is being reinforced by improved analytics and AI-enabled prioritization, but success remains dependent on experimental validation and robust clinical evidence. Organizations that align platform innovation with manufacturing discipline, regulatory engagement, health-system realities, and patient needs will be best positioned to translate gene-silencing science into durable clinical value.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. siRNA Therapeutics Market, by Drug Agent
7.1. Introduction
7.2. Givosiran
7.3. Inclisiran
7.4. Lumasiran
7.5. Nedosiran
7.6. Patisiran
7.7. Vutrisiran
8. siRNA Therapeutics Market, by Delivery Systems
8.1. Introduction
8.2. Lipid Nanoparticles
8.3. Peptide Delivery Systems
8.4. Polymer Conjugates
9. siRNA Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Intravenous (IV)
9.3. Subcutaneous
10. siRNA Therapeutics Market, by Therapeutic Categories
10.1. Introduction
10.2. Cardiovascular Disorders
10.3. Immunological Disorders
10.4. Infectious Diseases
10.4.1. Bacterial Infections
10.4.2. Viral Infections
10.5. Metabolic Disorders
10.6. Neurological Disorders
10.6.1. Alzheimer's Disease
10.6.2. Parkinson's Disease
10.7. Oncology
10.7.1. Hematologic Malignancies
10.7.1.1. Leukemia
10.7.1.2. Lymphoma
10.7.2. Solid Tumors
10.7.2.1. Breast Cancer
10.7.2.2. Lung Cancer
10.7.2.3. Prostate Cancer
11. siRNA Therapeutics Market, by End-User
11.1. Introduction
11.2. Contract Research Organizations
11.3. Hospitals & Clinics
11.4. Pharmaceutical Companies
11.5. Research & Academic Institutes
12. siRNA Therapeutics Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. siRNA Therapeutics Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. siRNA Therapeutics Market, by Country
14.1. Introduction
14.2. United States
14.3. Germany
14.4. China
14.5. United Kingdom
14.6. India
14.7. Japan
14.8. Russia
14.9. Brazil
14.10. Canada
14.11. Italy
14.12. Mexico
14.13. France
14.14. Spain
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Alnylam Pharmaceuticals Inc.
16.2. Alys Pharmaceuticals Inc.
16.3. Arbutus Biopharma Corporation
16.4. Arcturus Therapeutics, Inc. by Alcobra Ltd.
16.5. Aro Biotherapeutics Co.
16.6. Arrowhead Pharmaceuticals Inc.
16.7. Atalanta Therapeutics
16.8. Biocon Ltd.
16.9. e-Therapeutics Plc
16.10. Eli Lilly and Company
16.11. Ionis Pharmaceuticals Inc.
16.12. Merck & Co. Inc.
16.13. Moderna Therapeutics
16.14. Novartis AG
16.15. Novo Nordisk A/S
16.16. Phio Pharmaceuticals, Inc.
16.17. Quark Pharmaceuticals inc.
16.18. Risen Pharma Tech Co Ltd
16.19. Roche Holding AG
16.20. Shanghai Argo Biopharmaceutical Co., Ltd.
16.21. Silence Therapeutics plc
16.22. Sirius Therapeutics Inc.
16.23. Sirnaomics Inc.
16.24. Suzhou Sanegene Bio Inc.
16.25. Synerk Inc.
16.26. Thermo Fisher Scientific Inc.
16.27. Vir Biotechnology, Inc.
16.28. Wave Life Sciences USA, Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global siRNA Therapeutics Market, Years Considered for the Study
FIGURE 2. Global siRNA Therapeutics Market, Research Design
FIGURE 3. Global siRNA Therapeutics Market, Research Framework
FIGURE 4. Global siRNA Therapeutics Market, Data Triangulation
FIGURE 5. Global siRNA Therapeutics Market Size, 2017-2032 (USD Million)
FIGURE 6. Global siRNA Therapeutics Market Size, by Drug Agent, 2025 vs 2032 (%)
FIGURE 7. Global siRNA Therapeutics Market Size, by Drug Agent, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global siRNA Therapeutics Market Size, by Delivery Systems, 2025 vs 2032 (%)
FIGURE 9. Global siRNA Therapeutics Market Size, by Delivery Systems, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global siRNA Therapeutics Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 11. Global siRNA Therapeutics Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global siRNA Therapeutics Market Size, by Therapeutic Categories, 2025 vs 2032 (%)
FIGURE 13. Global siRNA Therapeutics Market Size, by Therapeutic Categories, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global siRNA Therapeutics Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 15. Global siRNA Therapeutics Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global siRNA Therapeutics Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global siRNA Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global siRNA Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global siRNA Therapeutics Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global siRNA Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global siRNA Therapeutics Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global siRNA Therapeutics Market Segmentation & Coverage
TABLE 2. Global siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 3. Global siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 4. Global Givosiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Givosiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Givosiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Inclisiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Inclisiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Inclisiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Lumasiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Lumasiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Lumasiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Nedosiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Nedosiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Nedosiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Patisiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Patisiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Patisiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Vutrisiran Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Vutrisiran Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Vutrisiran Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 23. Global Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Peptide Delivery Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Peptide Delivery Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Peptide Delivery Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Polymer Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Polymer Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Polymer Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 33. Global Intravenous (IV) Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Intravenous (IV) Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Intravenous (IV) Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 40. Global Cardiovascular Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Cardiovascular Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Cardiovascular Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Immunological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Immunological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Immunological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Bacterial Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Bacterial Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Bacterial Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Viral Infections Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Viral Infections Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Viral Infections Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Alzheimer's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Alzheimer's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Alzheimer's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Hematologic Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Hematologic Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Hematologic Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Leukemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Leukemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Leukemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 92. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Research & Academic Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Research & Academic Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Research & Academic Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 116. North America siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. North America siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 118. North America siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 119. North America siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 120. North America siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 121. North America siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 122. North America siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 123. North America siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 124. North America siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 125. North America siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 126. North America siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 127. Latin America siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Latin America siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 129. Latin America siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 130. Latin America siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 131. Latin America siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 132. Latin America siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 133. Latin America siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 134. Latin America siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 135. Latin America siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 136. Latin America siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 137. Latin America siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 138. Europe siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Europe siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 140. Europe siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 141. Europe siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 142. Europe siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 143. Europe siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 144. Europe siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 145. Europe siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 146. Europe siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 147. Europe siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 148. Europe siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 149. Middle East siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Middle East siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 151. Middle East siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 152. Middle East siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 153. Middle East siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 154. Middle East siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 155. Middle East siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 156. Middle East siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 157. Middle East siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 158. Middle East siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 159. Middle East siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 160. Africa siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Africa siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 162. Africa siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 163. Africa siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 164. Africa siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 165. Africa siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 166. Africa siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 167. Africa siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 168. Africa siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 169. Africa siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 170. Africa siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 171. Global siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. ASEAN siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 173. ASEAN siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 174. ASEAN siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 175. ASEAN siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 176. ASEAN siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 177. ASEAN siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 178. ASEAN siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 179. ASEAN siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 180. ASEAN siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 181. ASEAN siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 182. ASEAN siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 183. GCC siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 184. GCC siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 185. GCC siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 186. GCC siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 187. GCC siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 188. GCC siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 189. GCC siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 190. GCC siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 191. GCC siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 192. GCC siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 193. GCC siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 194. European Union siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. European Union siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 196. European Union siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 197. European Union siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 198. European Union siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 199. European Union siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 200. European Union siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 201. European Union siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 202. European Union siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 203. European Union siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 204. European Union siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 205. BRICS siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 206. BRICS siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 207. BRICS siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 208. BRICS siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 209. BRICS siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 210. BRICS siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 211. BRICS siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 212. BRICS siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 213. BRICS siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 214. BRICS siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 215. BRICS siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 216. G7 siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 217. G7 siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 218. G7 siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 219. G7 siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 220. G7 siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 221. G7 siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 222. G7 siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 223. G7 siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 224. G7 siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 225. G7 siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 226. G7 siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 227. NATO siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 228. NATO siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 229. NATO siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 230. NATO siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 231. NATO siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 232. NATO siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 233. NATO siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 234. NATO siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 235. NATO siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 236. NATO siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 237. NATO siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 238. Global siRNA Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 239. United States siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 240. United States siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 241. United States siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 242. United States siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 243. United States siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 244. United States siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 245. United States siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 246. United States siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 247. United States siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 248. United States siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 249. United States siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 250. Germany siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 251. Germany siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 252. Germany siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 253. Germany siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 254. Germany siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 255. Germany siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 256. Germany siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 257. Germany siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 258. Germany siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 259. Germany siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 260. Germany siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 261. China siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 262. China siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 263. China siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 264. China siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 265. China siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 266. China siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 267. China siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 268. China siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 269. China siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 270. China siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 271. China siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 272. United Kingdom siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 273. United Kingdom siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 274. United Kingdom siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 275. United Kingdom siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 276. United Kingdom siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 277. United Kingdom siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 278. United Kingdom siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 279. United Kingdom siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 280. United Kingdom siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 281. United Kingdom siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 282. United Kingdom siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 283. India siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 284. India siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 285. India siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 286. India siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 287. India siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 288. India siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 289. India siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 290. India siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 291. India siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 292. India siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 293. India siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 294. Japan siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 295. Japan siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 296. Japan siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 297. Japan siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 298. Japan siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 299. Japan siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 300. Japan siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 301. Japan siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 302. Japan siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 303. Japan siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 304. Japan siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 305. Russia siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 306. Russia siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 307. Russia siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 308. Russia siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 309. Russia siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 310. Russia siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 311. Russia siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 312. Russia siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 313. Russia siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 314. Russia siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 315. Russia siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 316. Brazil siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 317. Brazil siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 318. Brazil siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 319. Brazil siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 320. Brazil siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 321. Brazil siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 322. Brazil siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 323. Brazil siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 324. Brazil siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 325. Brazil siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 326. Brazil siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 327. Canada siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 328. Canada siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 329. Canada siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 330. Canada siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 331. Canada siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 332. Canada siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 333. Canada siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 334. Canada siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 335. Canada siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 336. Canada siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 337. Canada siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 338. Italy siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 339. Italy siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 340. Italy siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 341. Italy siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 342. Italy siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 343. Italy siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 344. Italy siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 345. Italy siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 346. Italy siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 347. Italy siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
TABLE 348. Italy siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
TABLE 349. Mexico siRNA Therapeutics Market Size, 2017-2032 (USD Million)
TABLE 350. Mexico siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
TABLE 351. Mexico siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
TABLE 352. Mexico siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 353. Mexico siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
TABLE 354. Mexico siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
TABLE 355. Mexico siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 356. Mexico siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 357. Mexico siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
TABLE 358. Mexico

Companies Mentioned

  • Alnylam Pharmaceuticals Inc.
  • Alys Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics, Inc. by Alcobra Ltd.
  • Aro Biotherapeutics Co.
  • Arrowhead Pharmaceuticals Inc.
  • Atalanta Therapeutics
  • Biocon Ltd.
  • e-Therapeutics Plc
  • Eli Lilly and Company
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Moderna Therapeutics
  • Novartis AG
  • Novo Nordisk A/S
  • Phio Pharmaceuticals, Inc.
  • Quark Pharmaceuticals inc.
  • Risen Pharma Tech Co Ltd
  • Roche Holding AG
  • Shanghai Argo Biopharmaceutical Co., Ltd.
  • Silence Therapeutics plc
  • Sirius Therapeutics Inc.
  • Sirnaomics Inc.
  • Suzhou Sanegene Bio Inc.
  • Synerk Inc.
  • Thermo Fisher Scientific Inc.
  • Vir Biotechnology, Inc.
  • Wave Life Sciences USA, Inc.

Related Topics

Related Reports

Small Nucleic Acid Therapies Market - Global Forecast 2026-2032 - Product Image

Small Nucleic Acid Therapies Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Antibody-oligonucleotide Conjugates Market - Global Forecast 2026-2032 - Product Image

Antibody-oligonucleotide Conjugates Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Cell Penetrating Peptides - Global Strategic Business Report - Product Image

Cell Penetrating Peptides - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Microfluidics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Microfluidics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 168 Pages
  • Global
From
Antisense Oligonucleotides Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antisense Molecule, Type of ASO Generation, Target Disease Indication, Route of Administration, Type of Therapy, and Geography - Product Image

Antisense Oligonucleotides Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Antisense Molecule, Type of ASO Generation, Target Disease Indication, Route of Administration, Type of Therapy, and Geography

  • Report
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.